drugset / Trial / NCT06389526
A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary purpose of this trial is to assess the tolerability and safety of CHS-1000 alone and in combination with toripalimab-tpzi in participants with advanced solid tumors.
Timeline
- Start
- 2025-02-15
- Primary completion
- 2028-05-30
- Completion
- 2028-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CHS-1000 | Unknown | — | — |
| Subject | Toripalimab | Monoclonal antibody | — | — |
Indications
No indication recorded.